Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a new autoinjector pen option for Cyltezo, an interchangeable biosimilar to Humira. Cyltezo ...

Humira (adalimumab) is a prescription drug used for various conditions, including rheumatoid arthritis and plaque psoriasis. Mild side effects of the drug include injection site reactions, headache, ...

Humira (adalimumab) is a prescription drug that’s used to treat certain types of arthritis and other inflammation-related diseases. It comes as a liquid solution for injection under your skin. Humira ...

Celltrion USA is offering an 80 mg dose of Yuflyma (adalimumab-aaty), a high-concentration (100mg/ml) and citrate-free formulation of Humira (adalimumab) biosimilar, in the United States. Yuflyma is ...

(Reuters) -Amgen Inc said on Tuesday it launched a biosimilar version of AbbVie Inc's big selling arthritis treatment, the first such competition for Humira in the United States. Amgen said its drug, ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

July 5 (Reuters) - South Korea's Celltrion Healthcare (091990.KQ), opens new tab has launched a copycat version to AbbVie Inc's (ABBV.N), opens new tab Humira at about a 5% discount, adding to the ...